Stem cell-based therapies and immunomodulatory approaches in newly diagnosed type 1 diabetes

Current Stem Cell Research and Therapy

Volumn 6, Issue 1, 2011, Pages 10-15

  Couri, Carlos Eduardo Barra ^a   Voltarelli, Júlio César ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hemocentro Regional de Ribeirão Preto ^*  (Brazil)

Author keywords

Diabetes mellitus; Immune intervention; P cell precursors; P cell preservation; P cell regeneration; Stem cell

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIBODY; ANTIDIABETIC AGENT; AZATHIOPRINE; CARBOXYLASE; CYCLOSPORIN; DIAPEP277; ETANERCEPT; GLUTAMIC ACID; GLUTAMIC ACID DESCARBOXYLASE ALUM; HEAT SHOCK PROTEIN; IMMUNOMODULATING AGENT; INSULIN; MONOCLONAL ANTIBODY CD3; T CELL GLOBULIN ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; CELL REGENERATION; DIABETES CONTROL; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ANIMALS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; INSULIN-SECRETING CELLS; REGENERATION; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 79551671049     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488811794480690     Document Type: Article

References (56)

1. American Diabetes Association. Diagnosis and Classification of Diabetes. Diabetes Care 2004; 27 (Suppl I): S5-S10.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
3. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 1999; 15: 205-18.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
5. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G; EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373: 2027-33.
6. Marshall AL, Chetwynd A, Morris JA, et al. Type 1 diabetes mellitus in childhood: a matched case control study in Lancashire and Cumbria, UK. Diabet Med 2004; 21: 1035-40.
7. Notkins AL, Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 2001; 108: 1247-52.
8. Pozzilli P, Di Mario U. Autoimune diabetes not requiring insulin at diagnosis (latent autoimune diabetes of the adult). Diabetes Care 2001; 24: 1460-7.
9. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve p-cell function. Diabetes 2004; 53: 250-64.
10. Redondo MJ, Rewers M, Yu L, Pilcher CC, Elliott RB, Eisenbarth G. Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin, and non-twin siblings of patients with type 1A diabetes: prospective twin study. BMJ 1999; 318: 698-702.
11. Bennett ST, Todd JA. Human type 1A diabetes and the insulin gene: principles of mapping polygenes. Annu Rev Genet 1996; 30: 343-70
12. Fairweather D L, Rose NR. Type 1 diabetes: virus infection or autoimmune disease? Nat Immunol 2002; 3: 383-40.
13. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ 2004; 328: 750-4.
14. Eizirik DL, Mandrup-Poulsen T. A choice of death: the signal transduction of immune-mediated p-cell apoptosis. Diabetologia 2001; 44: 2115-33.
15. Eizirik DL, Kutlu B, Rasschaert J, Darville M, Cardozo AK. Use of microarray analysis to unveil transcription factor and gene networks contributing to p-cell dysfunction and apoptosis. Am N Y Acad Sci 2003; 1005: 55-74.
16. Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic p-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005; 54(Suppl 2): S97-S107.
17. The Epidemiology of Diabetes Interventions and Complications Research Group. The effect of intensive insulin therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-9.
18. Bonner-Weir S, Sharma A. Pancreatic stem cells. J Pathol 2002; 197: 519-26.
19. Swenne I. Pancreatic beta-cell growth and diabetes mellitus. Diabetologia 1992; 35: 193-201.
20. Fernandes A, King LC, Guz Y, Stein R, Wright CV, Teitelman G. Differentiation of new insulin-producing cells is induced by injury inadult pancreatic islets. Endocrinology 1997; 138:1750-62.
21. Finegood DT, Scaglia L, Bonner-Weir S. Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes 1995; 44: 249-56.
22. Kuroda A, Yamasaki Y, Imagawa A. Beta-cell regeneration in a patient with type 1 diabetes mellitus who was receiving immunosuppressive therapy. Ann Intern Med 2003; 139: W81.
23. Georgia S, Blushan A. p-cell replication is the primary mechanism of maintaining postnatal p-cell mass. J Clin Invest 2004; 114: 963-8.
24. Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004; 429: 41-6.
25. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007; 117: 2559-61.
26. Seaberg R, Smukler SR, Kieffer TJ, et al. Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages. Nat Biotechnol 2004; 22: 1115-24.
27. Bonner-Weir S, Taneja M, Weir GC, et al. In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci USA 2000; 97: 7999-8004.
28. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult bone marrow. Nature 2002; 418: 41-9.
29. Chen LB, Jiang XB, Yang L. Differentiation of rat marrow mesenchymal stem cells into pancreatic islet beta-cells. World J Gastroenterol 2004; 10: 3016-3020.
30. Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells from human marrow home to promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 2006; 103: 17438-43.
31. Urbán VS, Kiss J, Kovács J, et al. Mesenchymal Stem Cells Cooperate with Bone Marrow Cells in Therapy of Diabetes. Stem Cells 2008; 26: 244-53.
32. Petersen BE, Goff JP, Greenberger JS, Michalopoulos GK. Hepatic oval cells express the hematopoietic stem cell marker Thy-1 in the rat. Hepatology 1998; 27: 433-5.
33. Yang L, Li S, Hatch H, et al. In vitro transdifferentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. Proc Natl Acad Sci USA 2002; 99: 8078-8083.
34. Kim S, Shin JS, Kim HJ, Fisher RC, Lee MJ, Kim CW. Streptozotocin-induced diabetes can be reversed by hepatic oval cell activation through hepatic trans differentiation and pancreatic islet regeneration. Lab Invest 2007; 87: 702-12.
35. Kodama S, Kühtreiber W, Fujimura S, Dale EA, Faustman DL. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 2003; 14: 1223-7.
36. Chong AS, Shen J, Tao J, Yin D, Kuznetsov A, Hara M, Philipson LH. Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta-cell regeneration. Science 2006; 311:1774-5
37. Assady S, Maor G, Amit M, Itskovitzs-Eldor J, Skorecki KL, Tzukerman M. Insulin production by human embryonic stem cells. Diabetes 2001; 50: 1691-7.
38. Hansson M, Tonning A, Frandsen U, et al. Artifactual insulin release from differentiated embryonic stem cells. Diabetes 2004; 53: 2603-9.
39. Couri, CEB, Voltarelli JC. Potencial Role of Stem Cell Therapy in Type 1 Diabetes Mellitus. Arq Bras Endocrinol Metab 2008; 52: 407-15.
40. Couri CE, Foss MC, Voltarelli JC. Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting beta-cell regeneration. Braz J Med Biol Res 2006; 39: 1271-80.
41. Elliott RB, Berryman CC, Crossley JR, James AG. Partial preservation of pancreatic p-cell function in children with diabetes. Lancet 1981; 19: 631-2.
42. Harrison LC, Colman PG, Dean B, Baxter R, Martin FI. Increased in remission rate in newly diagnosed type l diabetic subjects treated with azathioprine. Diabetes 1985; 34: 1306-8.
43. Cook JJ, Hudson I, Harrison LC, et al. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 1989; 38: 779-83.
44. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Jonhson S. Immuno suppression with azatioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988; 319: 599-604.
45. Assan R, Feutren G, Sirmai J, et al. Plasma C-peptide levels and clinical remissions in recent-onset type 1 diabetic patients treated with cyclosporin A and insulin. Diabetes 1990; 39: 768-74.
46. Bougnères F, Landais P, Boisson C, et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990; 39: 1264-72.
47. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibodiy in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692-8.
48. Keymeulen B, Vandemeulebroucke E, Ziegler AG. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-608.
49. Raz I, Elias D, Avron A, Metzger M, Cohen IR. Beta-cell function in newly-onset type 1 diabetes and immuno modulation with a heat shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001; 358: 1749-53.
50. Saudek F, Havrdova T, Boucek P, Novota P, Skibova J. Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud 2004; 1: 80-8.
51. Ludvigsson J, Faresjo M, Hjorth M. GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes. N Engl J Med 2008; 359: 1909-20.
52. Mastrandrea L, Yu J, Behrens T, et al. Etanercept Treatment in Children with New Onset Type 1 Diabetes: Pilot Randomized, Placebo-Controlled, Double Blind Study. Diabetes Care 2009; 32: 1244-9.
53. Voltarelli JC, Couri CEB, Stracieri ABPL. Autologous Nonmyelo-ablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus. JAMA 2007; 297: 1568-76.
54. Couri CE, Oliveira MC, Stracieri AB. C-peptide levels and insulin independence following autologous nonmyeloablative hema-topoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009; 301: 1573-9.
55. Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: Getting closer to a cure? Blood 2002; 99: 768-84.
56. th Scientific Session. New Orleans. Abstract 24-OR 2009.